ArcherDX Announces Close of $55 Million Series C Financing

Proceeds to Support Registration and Launch of STRATAFIDE™ Pan-Solid Tumor Companion Diagnostic (CDx) and Development of Personal Cancer Monitoring (PCM) Surveillance Platform Products Designed to Expand Adoption of Personalized Medicine by Enabling Hea... Diagnostics, Venture Capital ArcherDX, Anchored Multiplex PCR, polymerase chain reaction
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news